Gland Pharma Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uieevkwkrtg8c16fjh574uh8.pdf

Key Takeaways


Revenue Headwinds: Supply, Inventory & Competition

Srinivas Sadu: "We are seeing that, as we speak, some players exiting the space. It is that the temporary blip where we are also supplying products to these companies, but when they exit, there will be a revenue pressure. But then it's also in long term, it's good because the competition is getting reduced."

Margin Strategy: Protect Price, Improve Internally

Srinivas Sadu: "One way is do we want to compromise on your margin and then go aggressively on the top line and which we are reluctant to do because then it's a permanent damage you're going to cause for the market."

Product-Specific Dynamics

Srinivas Sadu: "Stopper manufacturing and glass manufacturing is not our area of expertise, so we can't really manufacture those. And at the scale at which these are manufactured overall, this is like a situation once in a lifetime."

Growth Levers: Transfers, China & Capacity

Srinivas Sadu: "With Cenexi acquisition where the entire 100% of the revenue comes from the CDMOs, our mix actually improves because the competition what we're seeing in the generic space will get diluted a bit because we are more stronger CDMO players in that sense."

Working Capital & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Cenexi acquisition closeDeal closure expectedMarch–April 2023
Stopper second-source approvalCBE30 submitted; approval expectedNext month or two
China first product approvalOne product (~$100M market) in advanced reviewAnytime: Jan, Feb, or next quarter
Product transfers from FDA-hit competitorsSeveral products under discussion, some at agreement stage; positive contribution expectedQ1 FY24
Pashamylaram line commercializationOne line this quarter, two more next quarterCurrent quarter and next quarter
Complex injectable approvalsOne or two products expected to receive approvalsFY24
Cash conversion cycle normalizationIncreased receivable and inventory days expected to normalizeNo specific date; expectation stated
Gross marginMaintain current levelOngoing; market-dependent
R&D spendRemain at ~5–5.5% of revenue, no significant increaseOngoing
Overall growth recoveryGrowth expected to come backFiscal 2024 (estimate)

Key Metrics

MetricQ3 FY23
Revenue from operations₹938.3 cr, down 12% YoY
Revenue from operations (9M FY23)₹2,839.6 cr, down 14% YoY
Gross marginImproved QoQ due to geography and product mix; 9M stable YoY
EBITDA₹351.1 cr, down 11% YoY
EBITDA margin (excl. other income)31% for Q3, 30% for 9M FY23
Net profit (PAT)₹231.9 cr, down 15% YoY
PAT margin23% for Q3 and 9M FY23
Other income₹61.5 cr, includes interest on fixed deposits and forex gains
R&D expenditure (total)₹51.2 cr, 5.5% of revenue vs 6.6% in Q3 FY22
R&D expenditure (excl. capital R&D)₹50 cr, 5.3% of revenue vs ₹39.4 cr in Q2 FY23
Effective tax rate~25% for Q3, 26% for 9M FY23
Cash flow from operations (Q3)₹39.8 cr
Cash flow from operations (9M FY23)₹435.4 cr
Cash and bank balances₹3,829.7 cr as of Dec 2022
Total capex incurred (9M FY23)₹125.3 cr
Capex guidance₹200–250 cr for FY23, ₹300 cr for FY24
Working capital₹2,332.2 cr as of Dec 2022, up from ₹2,021.7 cr in Mar 2022
Average cash conversion cycle246 days for 9M ending Dec 2022 vs 190 days in same period last year
ROCE (ex-cash, annualized)20% for 9M FY23
Fixed assets turnover2.4x for 9M FY23 vs 3.2x in same period last year
Profit share9% of revenue vs 7% in Q2 FY23 and 10% in Q3 FY22
Core markets revenue share70% of Q3 revenue, similar to Q3 FY22
Rest-of-the-world markets revenue share21% of Q3 revenue vs 19% in Q3 FY22
India market revenue share9% of Q3 revenue
ANDA filings completed in Q38 filings
Cumulative ANDA filings in the US325 as of Dec 2022, along with partners
Cumulative product registrations globally1,581 as of Dec 2022, along with partners
Enoxaparin annual revenue run rate (US)~$50 million; Q3 FY23 was ~$5 million due to timing
Complex injectable products filed4 total, combined market value ~₹200 cr
Biosimilar CDMO capex spent to date~₹300 cr
Pashamylaram plant lines8 currently, 3 under validation; expanding to 11 total
China product opportunityOne product near approval with market size of ~$100 million